Shield Therapeutics (LON:STX) Share Price Passes Below 50-Day Moving Average – Should You Sell?

Shield Therapeutics plc (LON:STX) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 3.06 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.10 ($0.04), with a volume of 893,979 shares changing hands.

Shield Therapeutics Stock Up 1.6 %

The company has a market cap of £30.59 million, a PE ratio of -0.80 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a fifty day moving average of GBX 3.06 and a two-hundred day moving average of GBX 3.39.

Insider Activity at Shield Therapeutics

In other Shield Therapeutics news, insider Anders Lundstrom bought 575,000 shares of Shield Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average price of GBX 4 ($0.05) per share, with a total value of £23,000 ($29,792.75). 62.16% of the stock is owned by insiders.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.